bluuebunny/crossref_metadata_2025_split huggingface dataset:
Community-based integrated tick management programs: cost and feasibility scenarios
Authors: Schulze Terry L , Eisen Lars , Russell Katie , Jordan Robert A 
Published: August 2023

Abstract
Numerous studies have assessed the efficacy of environmentally based control methods to suppress populations of the blacklegged tick (Ixodes scapularis Say), but few of these estimated the cost of control. We estimated costs for a range of tick control methods (including habitat management, deer exclusion or population reduction, broadcast of acaricides, and use of host-targeted acaricides) implemented singly or in combination and applied to a model community comprising 320 residential properties and parklands. Using the high end for cost ranges, tick control based on a single method was estimated to have mean annual costs per household in the model community ranging from $132 for treating only forest ecotone with a broadcast synthetic acaricide to kill host-seeking ticks (or $404 for treating all residential forested habitat) to &gt;$2,000 for deployment of bait boxes (SELECT TCS) across all residential tick habitat to treat rodents topically with acaricide to kill infesting ticks. Combining different sets of multiple methods in an integrated tick management program placed the annual cost between $508 and 3,192 annually per household in the model community, underscoring the disconnect between what people in Lyme disease endemic areas say they are willing to pay for tick control (not more than $100–150 annually) and the actual costs for tick control. Additional barriers to implementing community-based tick management programs within residential communities are discussed.
Appendiceal cancer showing a submucosal tumor-like morphology in the ascending colon on colonoscopy: a case report
Authors: Koshino Kurodo , Nakagawa Ryosuke , Tani Kimitaka , Ogawa Shimpei , Yamamoto Tomoko , Inoue Yuji , Yamaguchi Shigeki 
Published: August 2023

Abstract
Few reports have described a submucosal tumor (SMT)-like colon tumor together with appendiceal cancer. Moreover, some appendiceal tumors may exhibit a cecal protuberance. Here, we report an uncommon case of appendiceal cancer with an SMT-like tumor, which was a protuberant lesion in the ascending colon. To our knowledge, this is the first report in Japan. Our case was a 50-year-old man with an ascending colon tumor presented at our hospital for further evaluation of this lesion. This was discovered as a cystic lesion near the ascending colon on colonoscopy. Our initial diagnosis was an ascending colon SMT-like tumor, and our treatment strategy was laparoscopic resection. The differential diagnosis was appendiceal cancer or mucocele. Postoperative pathological findings led to a diagnosis of adenocarcinoma of the appendix. The postoperative course was uneventful, and the patient was followed up with computed tomography and blood sampling on an outpatient basis.
Primary leiomyosarcoma of the uterine cervix: an unusual case and critical appraisal
Authors: Lebbe Ines , De Cuypere Eveline , Claes Nele , Loccufier Anne , Ghysel Christophe , Van Trappen Philippe 
Published: August 2023

Abstract
Leiomyosarcomas of the uterine cervix are rare, mostly occurring in perimenopausal women. Diagnosis is based on pathology and immunohistochemistry. Surgery with a total abdominal hysterectomy and bilateral salpingo-oophorectomy remains the standard. A female patient in her 60s presented with heavy postmenopausal bleeding. Vaginal ultrasound scan and magnetic resonance imaging showed a large strongly vascularized cervical mass with features suspicious of sarcomatous degeneration. Positron Emission Tomography-Computed Tomography (PET-CT) did not reveal any evidence of metastases nor lymphadenopathy, but presence of right hydronephrosis. An abdominal hysterectomy with bilateral salpingo-oophorectomy, and end-to-end anastomosis of the right ureter, was performed. Pathology showed an International Federation of Gynecology and Obstetrics (FIGO)-stage 1B leiomyosarcoma of the uterine cervix. No adjuvant treatment was given. Adjuvant radiotherapy reduces the risk of recurrence but no survival impact. The benefit of adjuvant chemotherapy is questionable given the lack of randomized trials. Multidisciplinary research concerning molecular alterations of the disease is required to determine optimal management strategies with potential novel molecular therapies.
History of infertility and sexual dysfunction in midlife women: Is there a link?
Authors: Saadedine Mariam , Faubion Stephanie S , Kling Juliana M , Kuhle Carol , Shufelt Chrisandra L , Mara Kristin , Enders Felicity , Kapoor Ekta 
Published: August 2023

AbstractBackgroundInfertility has been linked with an increased risk of sexual dysfunction in reproductive-aged women, with longer periods of infertility associated with a greater risk.AimThe study’s aim was to examine whether a history of infertility treatment in women is linked to sexual dysfunction during midlife.MethodsThe cross-sectional study was conducted among sexually active women, between the ages of 45 and 65 years, who sought consultation at the women’s health clinics at a US tertiary care center. History of infertility treatment was assessed with a single question that asked participants if they were treated for infertility in the past. The association between a history of infertility treatment and sexual dysfunction—which was diagnosed by a combination of Female Sexual Function Index score ≤26.55 and Female Sexual Distress Scale–Revised score ≥11—was assessed in a multivariable logistic regression model that adjusted for multiple confounders.OutcomesThe primary outcome was sexual dysfunction in midlife women.ResultsThe analysis included 5912 women, with a mean age of 54.1 years. Nearly 16% of women reported receiving treatment for infertility. More than half the women (55%) had sexual dysfunction: 56.3% of those with previous fertility treatments and 54.4% of those without any fertility treatment (P = .3). Receiving treatment for infertility in the younger years did not significantly increase the odds of sexual dysfunction in midlife in univariate (odds ratio, 1.08; 95% CI, 0.94-1.24; P = .3) and multivariable analyses (odds ratio, 1.11; 95% CI, 0.96-1.29; P = .17).Clinical ImplicationsWhile infertility is known to be predictive of sexual dysfunction in women during their reproductive years, there was no association between a history of infertility treatment and sexual dysfunction in midlife women in the current study.Strengths and LimitationsThe study used validated questionnaires accounting for sexual complaints and distress and adjusted for multiple confounding factors. Limitations include the selection bias introduced by the study of women presenting for evaluation of sexual dysfunction, which may have been a result of factors stronger than the influence of infertility. Other limitations include the study’s cross-sectional nature with suboptimal racial and ethnic representation.ConclusionAlthough infertility is commonly associated with female sexual dysfunction in women of reproductive age, the association was not present in midlife women in the current study.
A Case of Whipple’s Disease With Concomitant Esophageal Candidiasis
Authors: Choi Ryan , Pazevic Alexander , Pak Kevin , Skaret Michael , Bachmann Angela , Wilkerson Rashad 
Published: August 2023

ABSTRACT
Whipple’s Disease (WD) is a rare disease caused by the infection of Tropheryma whipplei. It can lead to immunosuppression and a multitude of effects on different organ systems, resulting in a constellation of seemingly unrelated findings. Although treatment may appear straightforward, T. whipplei can be difficult to eradicate. We present the case of a 36-year-old male with months of progressively worsening watery diarrhea, migratory arthralgias, and weight loss. He had undergone an extensive evaluation for rheumatologic, oncologic, and infectious disorders without positive findings. Esophagogastroduodenoscopy and colonoscopy revealed esophageal candidiasis, Helicobacter pylori infection, and foamy macrophages in the lamina propria of the duodenum and ileum with positive polymerase chain reaction for T. whipplei. There were no other risk factors for esophageal candidiasis. He received treatment for his esophageal candidiasis and H. pylori infection and was treated for WD with ceftriaxone for 2 weeks, followed by hydroxychloroquine and doxycycline for 1 year. Symptoms resolved after 3 months of therapy. One year later, repeat bidirectional endoscopy was performed. Biopsies were negative for T. whipplei, although there were persistent foamy macrophages. There have been previously reported cases of patients with WD with concomitant esophageal candidiasis, and this association implies a likely state of relative immunosuppression associated with WD, which is thought to be the result of impaired T helper cell 1 activity. This impairment likely contributes to the high rate of relapse. Having a low threshold for repeat evaluation is advisable for recurrent symptoms, but long-term surveillance strategies are not clearly defined.
The loneliest galaxies in the Universe: a GAMA and Galaxy Zoo study on void galaxy morphology
Authors: Porter Lori E , Holwerda Benne W , Kruk Sandor , Lara-López Maritza , Pimbblet Kevin A , Henry Christopher P A , Casura Sarah , Kelvin Lee S 
Published: August 2023

ABSTRACT
The large-scale structure of the Universe is comprised of galaxy filaments, tendrils, and voids. The majority of the Universe’s volume is taken up by these voids, which exist as underdense, but not empty, regions. The galaxies found inside these voids are expected to be some of the most isolated objects in the Universe. This study, using the Galaxy and Mass Assembly (GAMA) and Galaxy Zoo surveys, aims to investigate basic physical properties and morphology of void galaxies versus field (filament and tendril) galaxies. We use void galaxies with stellar masses ($M_*$) of 109.35 M⊙ &lt; M* &lt; 1011.25 M⊙, and this sample is split by identifying two redshift-limited regions, 0 &lt; z &lt; 0.075 and 0.075 &lt; z &lt; 0.15. To find comparable objects in the sample of field galaxies from GAMA and Galaxy Zoo, we identify ‘twins’ of void galaxies as field galaxies within ±0.05 and ±0.15 dex of $M_*$ and specific star formation rate. We determine the statistical significance of our results using the Kolmogorov–Smirnov test. We see that void galaxies, in contrast with field galaxies, seem to be disc-dominated and have predominantly round bulges (with &gt;50 per cent of the Galaxy Zoo citizen scientists agreeing that bulges are present).
Measuring mass transfer of AM CVn binaries with a space-based gravitational wave detector
Authors: Wang Zijian , Cao Zhoujian , Zhang Xian-Fei 
Published: August 2023

ABSTRACT
The formation mechanism of AM CVn binary has not been well understood yet. Accurate measurements of the mass transfer rate can help us to determine the formation mechanism. But unfortunately such observation by electromagnetic means is quite challenging. One possible formation channel of AM CVn binary is a semidetached white dwarf binary. Such system emits strong gravitational wave radiation which could be measured by the future space-based detectors. We can simultaneously extract the mass transfer rate and the orbital period from the gravitational wave signal. We employ a post-Keplerian waveform model of gravitational wave and carry out a Fisher analysis to estimate the measurement accuracy of mass transfer rate through gravitational wave detection. Special attention is paid to the observed sources in Gaia Data Release 2. We found that we can accurately measure the mass transfer rate for those systems. Comparing to electromagnetic observations, gravitational wave detection improves the accuracy more than two orders of magnitude. Our results imply that the gravitational wave detection will help much in understanding the formation mechanism of AM CVn binaries.
Influences of dynamical disruptions on the evolution of pulsars in globular clusters
Authors: Oh Kwangmin , Hui C Y , Hong Jongsuk , Takata J , Kong A K H , Tam Pak-Hin Thomas , Li Kwan-Lok , Cheng K S 
Published: August 2023

ABSTRACT
By comparing the physical properties of pulsars hosted by core-collapsed (CCed) and non-core-collapsed (non-CCed) globular clusters (GCs), we find that pulsars in CCed GCs rotate significantly slower than their counterparts in non-CCed GCs. Additionally, radio luminosities at 1.4 GHz in CCed GCs are higher. These findings are consistent with the scenario that dynamical interactions in GCs can interrupt angular momentum transfer processes and surface magnetic field decay during the recycling phase. Our results suggest that such effects in CCed GCs are stronger due to more frequent disruptions of compact binaries. This is further supported by the observation that both estimated disruption rates and the fraction of isolated pulsars are predominantly higher in CCed GCs.
NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
Authors: Kotecha Rupesh , Chiang Veronica , Tom Martin C , Nabavizadeh Ali , Zan Elcin , Peddi Srinivas , Sulman Erik P , Siegel Barry A , Huang Jiayi , Brem Steven , Ware Marcus , Kesari Santosh , Parent Ephraim E , Pope Whitney B , Holmes Robin , Chau Albert , Teoh Eugene J , Chao Samuel T , Aboian Mariam 
Published: August 2023

Abstract

BACKGROUND
After radiation therapy (RT) for brain metastases (BM), differentiating radiation necrosis from tumor recurrence remains challenging. PURSUE (NCT04410367) evaluated various measures of lesion 18F-fluciclovine uptake to establish image interpretation criteria (IIC) for 18F-fluciclovine-PET to accurately diagnose recurrent BM.

METHODS
Patients with solid tumor BM and a previously irradiated ‘reference’ lesion equivocal for recurrence on MRI who were scheduled for craniotomy underwent 18F-fluciclovine-PET (185 MBq) &lt;42 days post-MRI and 1-21 days pre-craniotomy. Lesion 18F-fluciclovine uptake was qualitatively rated as ‘mild’ (up to blood pool), ‘moderate’ (above blood pool to parotid gland), or ‘marked’ (above parotid gland) by three independent blinded readers. The primary endpoint was diagnostic performance of different uptake thresholds on qualitative reads vs central histopathology. Secondary endpoints included diagnostic performance, based on different thresholds, of quantitative (e.g., lesion standardized uptake value [SUV]) and dynamic measures. IIC were determined by committee and subsequently used to assess the diagnostic performance of 18F-fluciclovine.

RESULTS
All 23 reference lesions from 23 enrolled patients underwent histopathological analysis; 10 (43%) were pathologically-confirmed BM recurrence. The highest performing qualitative measure was ‘marked’, rendering 92-100% sensitivity and 40-80% specificity across readers. SUVmax was a reader-independent, high-performing quantitative metric (AUC 0.87, SUVmax threshold 4.8, 80% sensitivity, 85% specificity). Dynamic measures did not add diagnostic value. Thus, IIC was established as: “Lesions with 18F-fluciclovine uptake of SUVmax equal to or greater than 4.8, or visually greater than the parotid gland, should be considered suspicious for recurrence. Otherwise, recurrence should be considered unlikely.” Application of the IIC resulted in 80% sensitivity, 77-85% specificity, 73-80% PPV, and 83-85% NPV across the readers.

CONCLUSIONS
PURSUE is the first prospective, multicenter trial to establish IIC for 18F-fluciclovine-PET for suspected recurrent BM after RT, verified by histopathology. Finalized IIC demonstrated excellent diagnostic performance for 18F-fluciclovine and will help evaluate 18F-fluciclovine-PET in future studies.
NEIM-11 DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS
Authors: Kim Lauren , De Feyter Henk , de Graaf Robin , Fulbright Robert , Liu Yanning , Rothman Douglas , Baehring Joachim , Blondin Nicholas , Kim Peter , Antonio Omuro , Chiang Veronica , Moliterno Jennifer , Omay Sacit Bulent , Piepmeier Joseph , Corbin Zachary 
Published: August 2023

Abstract

BACKGROUND
The Warburg Effect (WE) is a metabolic change in which tumors favor glycolysis over oxidative phosphorylation and has been linked to cancer aggressiveness. Mutations in the isocitrate dehydrogenase (IDH) genes in gliomas are associated with improved outcomes. We deployed a magnetic resonance (MR) spectroscopic imaging technique coined Deuterium Metabolic Imaging (DMI) to measure the WE in multiple brain tumor types.

METHODS
Twenty-one patients underwent DMI, acquired on a Bruker 4T MR scanner after oral administration of 0.75g/kg of deuterated glucose. The WE was defined as the ratio of deuterated lactate, representing glycolysis, over deuterated glutamate and glutamine, representing oxidative phosphorylation. We devised an interval scale from 0 to 2 for the WE

RESULTS
The Wilcoxon rank sum test was performed to detect differences between groups.

RESULTS
The WE measurements for the largest groups, by diagnosis, showed: glioblastoma (n=9, mean=1.67); astrocytoma, IDH-mutant, WHO grade 3 (n=2, mean=0.25); oligodendroglioma, WHO grade 3 (n=3, mean=0.5); low grade glioma, IDH-mutant (n=2, mean=0); and meningioma, WHO grade 2 (n=2, mean=0). The WE for high-grade tumors (n=15, mean=1.27) was significantly different from the WE for low-grade tumors (n=5, mean=0), with a p=0.010. The WE for IDH wild type gliomas (n=9, mean=1.67) was significantly different from the WE for IDH-mutant gliomas (n=9, mean=0.44), with a p=0.007. Analysis is ongoing.

CONCLUSIONS
DMI successfully and non-invasively detects the WE in many types of brain tumors. The WE was larger in high-grade tumors as compared to low-grade tumors, and the WE was larger in IDH wild type gliomas as compared to IDH-mutant gliomas. If validated with future studies, our results suggest that DMI is a useful tool to measure differences in the metabolism of brain tumors with different clinical behaviors.
SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
Authors: Kumthekar Priya , Youssef Michael , Blondin Nicholas , Azadi Amir , Piccioni David , Glantz Michael , Carillo Jose , Avgeropoulos Nicholas , Makar Sherif , Blouw Barbara , Natasha Anna , Fisher Deanna , Huynh Lan , Peters John , Sweed Nathan , Dugan Michael , Kesari Santosh 
Published: August 2023

Abstract

INTRODUCTION
Patients diagnosed with Leptomeningeal Metastasis (LM) have limited treatment options. However, they may benefit from targetable therapy. LM breast cancer patients with HER2 positive primary tumors treated with IT Trastuzumab experienced clinical benefit (Malani, 2020), and improved craniospinal PFS (Figura, 2019). HER2 amplification of the primary and metastatic tumors can be heterogeneous. Biocept’s CNSideTM is a CLIA validated Laboratory Developed Test and is used commercially at the discretion of Physicians to detect CSF tumor cells (CSF-TCs). We analyzed HER2 amplification on CSF-TCs in LM patients with breast-, upper GI cancer as well as Non-Small Cell Lung Cancer (NSCLC).

METHODS
CSF was collected from patients with suspected or confirmed LM having Breast Cancer (N=334 patients, N=181 evaluable), NSCLC (N=28 patients) or upper GI cancer (N=4 patients, N=2 evaluable). CSF TCs were tested for HER2 amplification by FISH using CNSide.

RESULTS
For the breast cancer patients, 38% (68/181) had HER2 FISH detected on CSF TCs, 60% (109/181) had a HER2 negative primary tumor of which 35% (38/109) had HER2 positive CSF-TCs. Furthermore, 8% (14/181) had an equivocal HER2 primary tumor, 21% (3/14) of which had HER2 positive CSF-TCs. For the NSCLC patients, 50% (14/28) showed HER2 amplification on the CSF-TCs. For the upper GI cancer patients, one patient had an equivocal HER2 primary tumor, and HER2 positive CSF-TCs.

CONCLUSION
HER2 amplification is detected on CSF-TCs of patients with LM having breast cancer, upper GI cancer or NSCLC cancer. For NSCLC patients, HER2 positivity in the LM can be associated with drug resistance. Patients who have a HER2 negative primary tumor can develop HER2 positive LM, allowing for an anti-HER2 targetable treatment. Additional studies are needed to establish the clinical utility of CNSide in the detection of HER2 on the CSF-TCs to direct treatment of anti-HER2 therapy in patients with LM.
TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA
Authors: Arrillaga-Romany Isabel , Lassman Andrew , McGovern Susan , Mueller Sabine , Nabors Louis Burt , van den Bent Martin , Vogelbaum Michael , Allen Joshua E , Melemed Allen S , Tarapore Rohinton , Wen Patrick , Cloughsey Timothy 
Published: August 2023

Abstract

BACKGROUND
H3 K27M-mutant diffuse midline glioma is a universally fatal malignancy primarily affecting children and young adults. While radiotherapy (RT) provides transient benefit, no effective systemic therapy is currently available and current standard of care is RT followed by monitoring. Dordaviprone (ONC201), a first-in-class imipridone, is an oral, blood-brain barrier penetrating, selective small molecule antagonist of dopamine receptor D2/3 (DRD2) and agonist of the mitochondrial protease ClpP. An integrated pooled analysis of five open-label trials previously demonstrated efficacy in dordaviprone-treated patients with recurrent disease. This phase 3 trial will be the first randomized, controlled study evaluating ONC201 in patients with H3 K27M-mutant disease.

METHODS
ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international Phase 3 study of ONC201 in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy will be randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on two consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS) in all participants; PFS will be assessed by response assessment in neuro-oncology-high grade glioma by blind independent central review. Other objectives include assessments of safety, additional efficacy endpoints, clinical benefit, quality of life, pharmacokinetics, biomarkers, and healthcare resource utilization. Eligible patients will have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility will not be restricted based on age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in the United States, with international sites opening imminently.